MHC class II expression on myeloid cells inversely correlates with disease progression in early rheumatoid arthritis

Rheumatology

Volumn 46, Issue 6, 2007, Pages 931-933

  Mueller, R B ^a,b   Skapenko, A ^a,b   Wendler, J ^c   Schuch, F ^c   Kalden, J R ^b   Schulze Koops, Hendrik ^a,b,d  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Rheumatologische Gemeinschaftspraxis   (Germany)

^d NONE   (Germany)

Author keywords

Macrophages; Monocytes; Rheumatoid arthritis

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE DESTRUCTION; BONE MARROW CELL; CELL DIFFERENTIATION; CELL ISOLATION; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MALE; MONOCYTE; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELLS, CULTURED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HLA-DR ANTIGENS; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; MYELOID CELLS; PILOT PROJECTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34447337995     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem025     Document Type: Article

References (11)

1. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotroxate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
2. Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: Results after 20 years. Lancet 1987;1:1108-11.
3. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
4. Mueller RB, Skapenko A, Grunke M et al. Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor. Arthritis Rheum 2005;52:451-60.
5. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts, Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
6. Giovagnoni A, Valeri G, Burroni E, Arnici F. Rheumatoid arthritis: follow-up and response to treatment. Eur J Radiol 1998;27:S25-30.
7. Young A, van der Heijde DM. Can we predict aggressive disease? Baillieres Clin Rheumatol 1997;11:27-48.
8. Gonzalez-Gay MA, Garcia-Porrua C, Hajeer AH. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum 2002;31:355-60.
9. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology 2000;39(Suppl. 1):24-9.
10. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR. Macrophages in rheumatoid arthritis. Arthritis Res 2000;2:189-202.
11. Prots I, Skapenko, A, Wendler J et al. Association of the IL4R single-nucleotide polymorphism 150V with rapidly erosive rheumatoid arthritis. Arthritis Rheum 2006;54:1491-500.